SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Thomas Ruhstaller, Marcus Vetter et al.|BMC Cancer|2016Cited by 46
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.Christoph Rochlitz, Ralph C. Winterhalder, Roger von Moos et al.|Journal of Clinical Oncology|2014Cited by 14
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN studySacha I. Rothschild, Markus Borner, Daniel Betticher et al.|Cancer Chemotherapy and Pharmacology|2019Cited by 8
Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)Roger von Moos, Arnoud J. Templeton, Hanne Hawle et al.|Annals of Oncology|2018Cited by 4